poisar

Stocks · News reference

Truist Securities Raises Price Target for ArriVent BioPharma

Fiscal.ai

Truist Securities has maintained its 'Buy' rating on ArriVent BioPharma while increasing the price target from $21.00 to $24.00 per share.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading